Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar 13;47(3):e149.
doi: 10.1038/emm.2015.3.

Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome

Bhumsoo Kim  1 , Eva L Feldman  1
Affiliations
Review

Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome

Bhumsoo Kim et al. Exp Mol Med. .

Abstract

Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors that includes obesity, diabetes, and dyslipidemia. Accumulating evidence implies that MetS contributes to the development and progression of Alzheimer's disease (AD); however, the factors connecting this association have not been determined. Insulin resistance (IR) is at the core of MetS and likely represent the key link between MetS and AD. In the central nervous system, insulin plays key roles in learning and memory, and AD patients exhibit impaired insulin signaling that is similar to that observed in MetS. As we face an alarming increase in obesity and T2D in all age groups, understanding the relationship between MetS and AD is vital for the identification of potential therapeutic targets. Recently, several diabetes therapies that enhance insulin signaling are being tested for a potential therapeutic benefit in AD and dementia. In this review, we will discuss MetS as a risk factor for AD, focusing on IR and the recent progress and future directions of insulin-based therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MetS and AD Aβ/tau pathology may act in a feed-forward mechanism to accelerate AD pathology in the presence of IR.
See this image and copyright information in PMC

References

    1. Duvnjak L, Duvnjak M. The metabolic syndrome—an ongoing story. J Physiol Pharmacol. 2009;60:19–24. - PubMed
    1. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Report. 2009;5:1–7. - PubMed
    1. Bruce KD, Hanson MA. The developmental origins, mechanisms, and implications of metabolic syndrome. J Nutr. 2010;140:648–652. - PubMed
    1. Sesti G. Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol Metab. 2006;20:665–679. - PubMed
    1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011;377:1019–1031. - PubMed

Publication types